Trials / Completed
CompletedNCT00078637
Dosing and Safety Study of E7820 in Patients With a Malignant Solid Tumor or Lymphoma
Phase I and Pharmacokinetic Study of E7820 After Oral Administration to Patients With Malignancy
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 37 (actual)
- Sponsor
- Eisai Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a first-in-man, open-label, non-randomized, multiple dose, multiple cycle, dose escalation study to determine the MTD, safety, PK, and pharmacodynamics of E7820 in patients with a malignant solid tumor or lymphoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | E7820 |
Timeline
- Start date
- 2004-01-01
- Primary completion
- 2006-08-01
- Completion
- 2007-02-01
- First posted
- 2004-03-05
- Last updated
- 2014-12-23
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00078637. Inclusion in this directory is not an endorsement.